MacroGenics (NASDAQ: MGNX) CEO converts RSUs and disposes shares at $1.81

Rhea-AI Filing Summary

MacroGenics (MGNX) President and CEO Eric Blasius Risser reported multiple equity award transactions in early February 2026. On February 7, 2026, 6,668 restricted stock units (RSUs) converted on a one-for-one basis into common stock, increasing his direct holdings to 62,657 shares before a 2,575-share disposition at $1.81 per share, leaving 60,082 shares.

On February 8, 2026, a further 11,166 RSUs converted into common stock, taking his direct common stock position to 71,248 shares before a 4,311-share disposition at $1.81 per share, resulting in 66,937 common shares directly owned. Following these transactions, he held 13,332 RSUs from a February 7, 2025 grant of 20,000 units and 11,166 RSUs from a February 8, 2024 grant of 33,500 units, each vesting in three equal annual installments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Risser Eric Blasius

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/07/2026		M		6,668	A	(1)	62,657	D
Common Stock	02/07/2026		F		2,575	D	$1.81	60,082	D
Common Stock	02/08/2026		M		11,166	A	(1)	71,248	D
Common Stock	02/08/2026		F		4,311	D	$1.81	66,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/07/2026		M			6,668	(2)	(2)	Common Stock	6,668	$0	13,332	D
Restricted Stock Unit	(1)	02/08/2026		M			11,166	(3)	(3)	Common Stock	11,166	$0	11,166	D

Explanation of Responses:

1. Restricted stock units convert into the Company's stock on a one-for-one basis.

2. On February 7, 2025, the reporting person was granted 20,000 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.

3. On February 8, 2024, the reporting person was granted 33,500 restricted stock units, vesting in three equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MacroGenics (MGNX) report for its CEO?

MacroGenics CEO Eric Blasius Risser reported RSU conversions and share dispositions in February 2026. RSUs totaling 6,668 and 11,166 shares converted into common stock, with 2,575 and 4,311 shares respectively disposed of at $1.81 per share.

How many MacroGenics (MGNX) shares does the CEO own after these Form 4 transactions?

After the reported transactions, Eric Blasius Risser directly owns 66,937 MacroGenics common shares. This figure reflects RSU conversions on February 7–8, 2026 and related dispositions at $1.81 per share disclosed in the Form 4.

What restricted stock unit grants are disclosed for the MacroGenics (MGNX) CEO?

The filing discloses two RSU grants to Eric Blasius Risser. He received 20,000 RSUs on February 7, 2025 and 33,500 RSUs on February 8, 2024, each vesting in three equal installments beginning on the first anniversary of the respective grant dates.

How do the RSUs convert into MacroGenics (MGNX) common stock?

Each restricted stock unit converts into one share of MacroGenics common stock. The filing states that RSUs convert on a one-for-one basis, and recent vesting events resulted in 6,668 and 11,166 common shares being issued to the CEO.

What prices were involved in the MacroGenics (MGNX) CEO’s share dispositions?

The CEO’s reported share dispositions were priced at $1.81 per share. On February 7, 2026, 2,575 shares were disposed of at this price, followed by 4,311 shares on February 8, 2026, as shown in the non-derivative transaction table.

What roles does Eric Blasius Risser hold at MacroGenics (MGNX) according to the filing?

Eric Blasius Risser is identified as both Director and President and CEO of MacroGenics. The Form 4 checkbox section confirms his status as a director and officer, with the officer title specifically listed as President and CEO.